Dear Investor,

Few analysts saw it coming . . .

But Cabot Small-Cap Confidential subscribers saw it as clearly as a wad of $1,000 bills in their hands.

The June 2009 issue arrived in their inboxes with an investment report on
a little-known company tearing up the markets in clean energy and electric grid management. 

See Below for Three Game-Changing Companies That Could Award You With A Life Of Leisure

No other analysts were following it.  Only four mutual funds owned it.  It was selling at a mere $2.67 a share.

That would soon change, however.  Because this company was no run-of-the-mill small-cap.

It had super growth and Big Profits written all over it.

Cabot Small-Cap Confidential editor Thomas Garrity told subscribers to buy the stock immediately.

The U.S. is the only country in the world with coal plants not cleaning emissions with a catalyst regeneration process, he wrote.  But these plants must now meet Washington’s stringent new emission standards.  And the best way is to use this company’s groundbreaking technology.

Information Asymmetry: The Key to Profits

Profits result from exploiting an information gap between the actual value of an important small cap and how Wall Street calculates its market value.

Wall Street is good at valuing companies based on current sales, earnings and profits.  But analysts seldom probe for information hidden deeply in companies – like products that are already disrupting their markets but haven't yet shown up in revenues.

So, a company's breakthrough products are often not accounted for in its share price.

The only way to uncover this explosive information is by researching companies on a Hedge Fund-level.  The reason Cabot Small-Cap Confidential is so successful is that Tom Garrity's research reveals explosive future growth that other analysts miss.  When the Street finally finds out what we already know, we sell our shares to them at hefty profits.

The company came with a bonus.  In addition to air-cleaning technology for coal plants, it also owned a game-changing mercury-removal process, and a smart grid technology and management system that lets electric utilities quickly and cost-effectively respond to fluctuating demand.

It was a pretty picture that almost no one else could see.

And it soon got prettier.

Almost immediately, subscribers who bought this stock were rewarded by a cascade of good news …

By August the stock had jumped 69% when the company announced that Q2 revenues were up 116% and gross profits had surged 238%.

Two months later, with the stock now approaching a 100% gain, the company’s CEO bought another 5,000 shares. 

Six weeks after that, the company reported a 40% increase in Q3 sales.

Now the stock was up 167% in just 21 weeks.  But then its gravity-defying price acceleration began to flatten.

In December, Tom instructed subscribers to take their original investments out of the stock.

Then, on January 15, 2010, he gave the sell signal. 

He was certain the company would soon deliver record-breaking earnings, after which the stock would be hard hit by profit taking.

And he wanted Cabot Small-Cap Confidential subscribers to bank their profits first.

The company’s name is Acorn Energy (Nasdaq: ACFN).  If you’d sold when Tom gave the signal, you could have notched a portfolio-building 112% profit in just seven months—an annualized gain of 192%.

Two weeks later, Acorn announced a 51% leap in year-over-year revenues.

$10,000 invested in Acorn would have brought you $21,200 in return—for doing practically nothing.

Finding Acorn Energy was no fluke. 

It was the result of the same hard-nosed, hedge fund-level research that led Tom to recommend Hansen Natural at the beginning of its massive 7,023% climb 10 years ago.

Acorn Energy is just one of the stocks pouring money into Cabot Small-Cap Confidential subscribers’ pockets. 

If you were already a subscriber, you could have scored a … …

• 63% profit in Depomed (DEPO)
• 40% profit in Orion Energy Systems (OESX)
• 24% gain in Airvana (AIRV)

That’s an additional 191% cumulative profit!

Imaging putting $10,000 in each of these winners.  You’d be another $59,100 richer today.  Not bad for eight month’s “work.”

You could use that capital to build an addition on your home, buy a new car with cash, pay tuition for a couple of years, or invest in an income property.

My point is this:

If you’re serious about making money in the market …

If you’re willing to invest in low-priced stocks with the potential to earn you millions …

If you believe that professional, hedge fund-level research can cut your risk today and earn you huge profits tomorrow …

And you don’t want to do the research yourself …

Then please read on.  This letter is for you.

The Best Is Yet To Come

There’s something I want you to know before we go any further. 

In spite of its price and exclusivity, Cabot Small-Cap Confidential isn’t a dry, academic investment report that you need an MBA in finance to figure out.

It’s one of the most fascinating “reads” you’ll ever encounter.  

You’ll get a full education on game-changing technologies in medicine, alternative energy, communications and environmental services.

I don’t mean wild-eyed predictions, what-if’s or science fiction fantasies.

I’m talking about actual, paradigm-shifting breakthroughs that are already being sold by the companies Tom recommends to you.

They’re as real as the car you drive.  They can save your life.  Make your cell phone smarter than you ever imagined.  Clean the air you breath. 

And they can make you insanely rich.

If you’re an investor who’s also intellectually curious, Cabot Small-Cap Confidential  will fascinate you, astound you, and excite you with a peek at the real-world that’s just around the corner—while it gives you the chance to make one of the most profitable investments of our time.  Guaranteed.

Three Game-Changing Companies That Could Award
You With A Life Of Leisure

New technologies are about to revolutionize everything from your cell phone to electric cars. 

Over two billion people will spend money to buy them.  But only a handful of “early bird” investors will become life-changing rich by investing in the companies bringing them to market. 

The trick is to invest in these kegs of dynamite now, before the market drives their shares sky high.

Companies like Intuitive Surgical and Hansen Natural have produced multi-generation fortunes for investors who saw their value early—before the market caught on.

The technologies featured in Cabot Small-Cap Confidential are already being sold or being used in production prototypes for next-generation products.

But the explosive revenues these breakthroughs will bring their companies are not yet reflected in their stock prices.

EXPLOSIVE GROWTH OPPORTUNITY #1

“Safe Blood” is About to Save Lives and Put Some Investors on the Highway of Wealth.
With the recent explosion of never-before-seen viruses, bacteria and parasites threatening the world’s blood supply, blood banks are faced with eradicating pathogens so new they often don’t know they exist.  This tiny company’s technology can eliminate pathogens no one knows are there.  Already 450,000 of its systems are being used in 11 countries, with a potentially $5 billion market in its sights.  This company is a major acquisition target, and it’s Tom’s second largest personal holding.  Very few investors understand just how huge this is going to be.  A $50,000 investment now could assure your family’s security for generations.  BUY NOW.              

EXPLOSIVE GROWTH OPPORTUNITY #2

Up 186% and Climbing As High As 1,000%.
This market leader’s breakthrough technology shatters all previous power/size ratios for electric motors.  Its 125 kW motor is already in most hybrid autos, and its 150 kW motor is powering large commercial vehicles.  It’s currently negotiating with the U.S. military to supply electric motors for tactical vehicles.  Electric vehicles are the wave of the future, and this future twenty-bagger is riding the wave to the bank.  It could be a $100+ million company by the time you read this.  This company is an unstoppable force.  The market is making a huge error by valuing this coming giant so cheaply.  BUY NOW.  

EXPLOSIVE GROWTH OPPORTUNITY #3

This Company’s System-on-a-Chip Could Earn You $20 for Every $1 You Invest.
System-on-a-chip (SOC) is a revolution in chip design that combines a microprocessor, memory, interfaces and peripherals onto a single semiconductor chip.  The result is vastly increased speed and functionality—as well as longer battery life—for the coming generation of Smartphones and other hand-helds.  This explosive company is the “go to” manufacturer for SOC.  Its 79.1% gross margin is one of the highest in the industry.  Sales are expected to double in 2010.  It has no debt.  And it’s grabbing an ever-larger share of a $1+ billion market.  Institutional investors are catching on, so expect a significant price movement soon.  BUY NOW. 

Here’s how confident Tom is in these and the other stocks he recommends:  he personally invests a large portion of his wealth in the majority of them.

A License to Print Money

When you invest in the stocks recommended by Cabot Small-Cap Confidential, you’re putting your money on undiscovered science and technology companies with monopolistic positions in their industries.   

Yes, monopolistic.

Tom won’t recommend a company unless it has a nearly uncrossable moat—a leadership position so vast that competitors can’t take market share or erode its margins for years to come. 

The moats in Cabot Small-Cap Confidential recommendations are scientific or clinical superiority, the number of products designed into other companies’ products, key strategic partnerships with major global manufacturers, and research teams dedicated to maintaining their leadership positions.

Wide moats = sustainable profits.

Every company you’ll invest in has a license to mint money.  And in every case, you’ll be a step ahead of Wall Street.  Once the big money catches on, our stocks can move very quickly.  For example …

• 63% profit in Depomed (DEPO) in eight months
• 40% profit in Orion Energy Systems (OESX) in eight months

And the beauty is, you don’t have to do any research yourself. 

Get Rich by Stealing from Venture Capitalists

Thomas E. Garrity
Analyst and Editor of Cabot Small-Cap Confidential

A lifelong investor, Tom has been a stockbroker, stock analyst, venture capitalist, and portfolio manager.  His extensive career has taught him to recognize and make investment recommendations only when in-depth analysis reveals that the odds of winning significantly outweigh the risks.

As of June 2010, one of Tom's portfolios earned a 278% compounded return over 6.6 years, and his second portfolio earned 484% compounded return over 11.6 years. Furthermore, Tom has participated in the Marketocracy Investment Challenge for more than 6.2 years, and his select portfolio has earned a compounded return of 418%.

I’ll let you in on a professional secret.

One of the key strategies for getting in on the ground floor of a massive opportunity is to learn what venture capitalists are funding.

No other class of investors recognizes breakthroughs in technology and medicine better than venture capitalists. 

So, as a Cabot Small-Cap Confidential subscriber, you’ll invest in markets that venture capitalists think have tremendous growth potential. 

But you’ll do none of the research.  Tom is an ex-venture capitalist, so he knows the players.  He casts a wide net among his contacts and zeros in on the hottest technologies and their markets.  

Then he finds the companies already leading in those markets.

You do nothing but reap the benefits.  You don’t have to analyze financial ratios, visit the companies you invest in, interview their executive teams, or follow recommended companies week by week.  Tom does all that for you.  All you have to do is invest in Cabot Small-Cap Confidential’s recommended stocks.

Since October 2009, Cabot Small-Cap Confidential has closed six positions with an average profit of 53%.   That’s about 6% per month between October ’09 and August ’10.

If you had invested in these winners, your cumulative gain would have been 321%, enough to turn $25,000 into $80,250 or $50,000 into $160,500. 

During the same period, the Wilshire 5000 was up only 3.8%.  And the Russell 2000 rose only 5.0%.

Our only two losers cost us 30%.

We intend to beat this stellar profit record this year.

So far, nine other companies in our portfolio are already up a cumulative 248%, including … 

Poised for a 400% Revenue Explosion.
Customers are lining up at the door for this future cash cow’s new design process that reduces chip design time from as much as 9 months to only three months.  Revenues are expected to skyrocket by 400% within two years.  Its 11% inside ownership points to committed management.  And it’s selling at a historically low price-to-sales ratio of 0.98.  Up 26% in two months.  This stock can reward you with a 500% or more gain once revenues start appearing on the bottom line.  BUY IMMEDIATELY. 

Cancer Cure?  Not Without This Company’s “Heat-Seeking Missiles.”
Monoclonal antibodies are revolutionizing cancer treatment because they deliver traditional anticancer drugs directly to cancer tumors, reducing the side effects of chemotherapy.  Cytoxins delivered by monoclonal antibodies can be administered in much higher doses.  In fact, this company’s technology has been shown to make one standard anticancer drug up to 1,000 times more effective.  This underappreciated gem already has a foothold in the $18 billion cancer treatment market, and its pipeline is packed with potential blockbuster drugs expected to be saving lives in as little as a few years.  It’s only a matter of time before doctors recognize that this company’s  technology is the best first-line cancer killer ever created.  It could turn $100,000 into $10,000,000.  BUY IMMEDIATELY.

Some of these low-price stocks have only begun to move.

And with the average price of our current recommendations at $6.23 …

They’re easily within reach of anyone reading this letter.  The upside could be in the millions of dollars.

Imagine what that would mean to your life.

But that’s not all. 

I’m sure you’re thinking about risk.  After all, these are small cap companies.

You can relax.

Because their technologies are so crucial, Cabot Small-Cap Confidential’s recommended companies are nearly 100% recession proof. 

They’re not bound by economic cycles.  They’re going to move whether the dollar, gold, and oil are going up or down.  They’ll be minimally affected by monetary policy, interest rates, inflation, or real estate … or China’s economy health … or the situation in the Middle East … or today’s headlines. 

If you’ve got capital to invest, you owe it to yourself to take a look at Cabot Small-Cap Confidential.

And did I mention this …

Having your stock acquired at a premium is an “early bonus” that investors love.   In the past few months, five of Cabot Small-Cap Confidential’s recommended companies have been acquired by larger companies for handsome premiums.

That tells you something about the quality of companies that you’ll invest in with Cabot Small-Cap Confidential.

And here’s a central reason why our companies tend to get acquired:

Every company on our BUY list must meet one ironclad criterion before Tom will recommend it.

The explosive revenues their technologies are about to bring to their bottom lines are not yet reflected in their stock prices . . . and Wall Street isn’t paying attention.   Yet.

Could any of our recommended companies head south?  To be honest, it’s possible.  But not probable.  That’s the beauty of in-depth, Hedge Fund-level research.  It reduces risk by sifting “story stocks” from companies with real, game-changing technologies that are rewriting the rules in their markets.

I’ve told you about only a fraction of Cabot Small-Cap Confidential’s portfolio.  Right now our portfolio also holds …

• A way-too-cheap market dominator whose software is installed in almost every cell phone that connects to a network.  Expected upside: 18%
   
• A pure play whose non-invasive treatment for enlarged prostates improves symptoms 80% better than Flomax … and can be done in 30 minutes in the doctor’s office.  
  
  
• A stealth giant that will make the screen on your next Smart phone so bright it won’t matter how brilliant the sun is. 
  
  
• A bargain-priced nutrapharmaceutical whose manufacturing process maintains the integrity of essential oils and antioxidants by preserving them in as close to their natural state as possible.

These stocks have increasing value in their DNA.  Any one of them could be what the last generation’s Top 5 profit exploders were before they became household names.

And they can make you very rich.

Membership Closing—Only 25 Seats Available

Cabot Small-Cap Confidential is Cabot’s most elite investment research service.  Its charter requires membership to be limited to only 500 investors. 

There are two reasons for this.

First, by restricting the number of seats available, we ensure that you can buy our recommended companies before others bid up their prices.

And second, you are entitled to personal access to editor Tom Garrity by email.  So, as I’m sure you understand, by limiting the number of subscribers, we keep the number of personal communications with him to a manageable number.

Take the Money and Run

More mega-millionaires in the past 30 years have been created by owning shares in small, technically advanced companies that were off Wall Street’s radar than in almost any other way.

Generations before us have had their moments of opportunity.  Think IBM. Southwest Airlines.  Walmart.  Microsoft.  Cisco.  Apple.  Dell.  For every investor who became a mega-millionaire in these stocks when they could, there are many more who did not.

Which category of investor would you prefer to be? 

Don’t miss this wake-up call.  You owe it to yourself to take a No-Risk look at Cabot Small-Cap Confidential.  The rewards can be enormous.  Reserve your place here.

FREE REPORT

When you join Cabot Small-Cap Confidential, you’ll automatically receive Tom Garriy’s 10 Rules for Investing in Tomorrow’s Top Stocks. 

Here, in one concise report, are the 10 rules that Tom Garrity has developed for small-cap investing.  These rules are the backbone of the methodology that has bulked up his clients’ portfolios over the past 25 years.  Every stock Tom recommends to you must pass the rigorous test these rules represent.

Use 10 Rules for Investing in Tomorrow’s Top Stocks as your own personal roadmap to become a smarter, savvier, and wealthier investor.

Click Here for Details of Your Complete, Hedge Fund-Level Research Package and Your Special $200 New Member Discount

Membership Will Be Closed As Soon As
We Reach 500 Subscribers

There are only 25 seats available at this time, and we expect them to fill quickly.

After that, it could be months, or even a year, until we’re able to accept new subscribers. 

Investing in Cabot Small-Cap Confidential is investing in yourself. 

Save $200 when you try Cabot Small-Cap Confidential. 

I’ve told you that Cabot Small-Cap Confidential is Cabot’s most expensive stock advisory service.

But there’s a way for you to claim one of the 25 available “seats” without paying the full cost, even with the $200 savings.  Get the details here.

“So far this year I have been doing so great with you guys.  I am a happy camper.  Absolutely no complains.  Thanks so much.” 
-- Jane

I guarantee Cabot Small-Cap Confidential will quickly become your most profitable investment service.  Join now!  Don’t let other investors fill the remaining 25 “seats.”

You’re just minutes away from our current portfolio of recommended companies.  Click here to see what they are. There is no risk!

I look forward to having you on board.

For your wealth,

Timothy Lutts
Publisher

P.S.  Any one of Cabot Small-Cap Confidential's current recommendations could duplicate Tom's 7,023% profit rocket in Hansen Naturals.  Don't risk missing the life-changing wealth it could bring you.  Take advantage of your introductory savings now.

P.P.S. As soon as the 25th reader of this letter subscribes, we will immediately stop accepting new subscribers.  Act now.

P.P.S.  Remember, as a subscriber, you're entitled to email editor Tom Garrity to discuss Cabot Small-Cap Confidential recommendations.  Take this opportunity to double or triple your money.